Cover Image

Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma

The objective of this retrospective analysis was to compare outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who received either a matched sibling (sib) or an unrelated donor (URD) allogeneic hematopoietic cell transplantation (allo-HCT). Long-term outcome of 172 DLBCL patients receiv...

Full description

Saved in:
Bibliographic Details
Main Authors: Avivi, Irit (Author) , Canals, C. (Author) , Vernant, J.-P. (Author) , Wulf, G. (Author) , Nagler, A. (Author) , Hermine, O. (Author) , Petersen, E. (Author) , Yakoub-Agha, I. (Author) , Craddock, C. (Author) , Schattenberg, A. (Author) , Niederwieser, D. (Author) , Thomson, K. (Author) , Blaise, D. (Author) , Attal, M. (Author) , Pfreundschuh, M. (Author) , Passweg, J. (Author) , Russell, N. (Author) , Dreger, Peter (Author) , Sureda, A. (Author)
Format: Article (Journal)
Language:English
Published: 10 February 2014
In: Bone marrow transplantation
Year: 2014, Volume: 49, Issue: 5, Pages: 671-678
ISSN:1476-5365
DOI:10.1038/bmt.2014.4
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bmt.2014.4
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bmt20144
Get full text
Author Notes:I Avivi, C Canals, J-P Vernant, G Wulf, A Nagler, O Hermine, E Petersen, I Yakoub-Agha, C Craddock, A Schattenberg, D Niederwieser, K Thomson, D Blaise, M Attal, M Pfreundschuh, J Passweg, N Russell, P Dreger, A Sureda on behalf of the EBMT Lymphoma Working Party
Description
Summary:The objective of this retrospective analysis was to compare outcomes of patients with diffuse large B-cell lymphoma (DLBCL) who received either a matched sibling (sib) or an unrelated donor (URD) allogeneic hematopoietic cell transplantation (allo-HCT). Long-term outcome of 172 DLBCL patients receiving URD-HCT between 2000 and 2007 and reported to the European Group for Blood and Marrow Transplantation, was compared with that of 301 subjects, allografted from sib-HCT. With a median follow-up of 45 months, 3-year PFS approached 35% for both groups; overall survival (OS) was 42% for sib-HCT versus 37% for URD (NS). Multivariate analyses confirmed that donor type was not associated with differences in non-relapse mortality (NRM), relapse rate (RR), PFS or OS. Poor performance status (PS) and refractory disease adversely affected PFS and OS. Prior auto-SCT and multiple previous therapies predicted for shorter PFS. NRM was adversely affected by older age (⩾50 years), poor PS and refractory disease, and RR by time from diagnosis to allo-HCT of <36 months, prior auto-SCT, refractory disease, poor PS and in vivo T-cell depletion with alemtuzumab. This large study shows for the first time that URD-HCT is not inferior to sib-HCT, providing a reasonable therapeutic approach for DLBCL patients, having no HLA-identical sibling available.
Item Description:Gesehen am 03.09.2020
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/bmt.2014.4

Similar Items